Area of research
Oncology · Immunology
Research interest
Research focused on Blockade and Brentuximab vedotin, with related work in Adverse effect, Immune system, PD-L1. Notable publications include 'Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer', 'Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial', and 'Long-term safety and efficacy of sapropterin: The PKUDOS registry experience'.
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Long-term safety and efficacy of sapropterin: The PKUDOS registry experience
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.